JP2016539134A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539134A5 JP2016539134A5 JP2016535691A JP2016535691A JP2016539134A5 JP 2016539134 A5 JP2016539134 A5 JP 2016539134A5 JP 2016535691 A JP2016535691 A JP 2016535691A JP 2016535691 A JP2016535691 A JP 2016535691A JP 2016539134 A5 JP2016539134 A5 JP 2016539134A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- inhibitor
- ezh2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 239000003112 inhibitor Substances 0.000 claims 11
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 10
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 102100026008 Breakpoint cluster region protein Human genes 0.000 claims 3
- 239000003862 glucocorticoid Substances 0.000 claims 3
- 229940124130 Bcl inhibitor Drugs 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000003827 upregulation Effects 0.000 claims 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 101000596277 Homo sapiens TSC22 domain family protein 3 Proteins 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 206010070308 Refractory cancer Diseases 0.000 claims 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims 1
- 102000043912 Sestrin Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 102100035260 TSC22 domain family protein 3 Human genes 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 210000001280 germinal center Anatomy 0.000 claims 1
- 229960001507 ibrutinib Drugs 0.000 claims 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 108700020508 sestrin Proteins 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 229960004066 trametinib Drugs 0.000 claims 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 1
- 229940099039 velcade Drugs 0.000 claims 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 1
- 229960001183 venetoclax Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913063P | 2013-12-06 | 2013-12-06 | |
| US61/913,063 | 2013-12-06 | ||
| US201461934388P | 2014-01-31 | 2014-01-31 | |
| US61/934,388 | 2014-01-31 | ||
| US201461992881P | 2014-05-13 | 2014-05-13 | |
| US61/992,881 | 2014-05-13 | ||
| PCT/US2014/069167 WO2015085325A1 (en) | 2013-12-06 | 2014-12-08 | Combination therapy for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019207594A Division JP2020045350A (ja) | 2013-12-06 | 2019-11-18 | 癌を治療するための併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016539134A JP2016539134A (ja) | 2016-12-15 |
| JP2016539134A5 true JP2016539134A5 (OSRAM) | 2018-01-25 |
Family
ID=53274220
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016535691A Pending JP2016539134A (ja) | 2013-12-06 | 2014-12-08 | 癌を治療するための併用療法 |
| JP2019207594A Pending JP2020045350A (ja) | 2013-12-06 | 2019-11-18 | 癌を治療するための併用療法 |
| JP2021180722A Active JP7323592B2 (ja) | 2013-12-06 | 2021-11-05 | 癌を治療するための併用療法 |
| JP2023122130A Pending JP2023139230A (ja) | 2013-12-06 | 2023-07-27 | 癌を治療するための併用療法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019207594A Pending JP2020045350A (ja) | 2013-12-06 | 2019-11-18 | 癌を治療するための併用療法 |
| JP2021180722A Active JP7323592B2 (ja) | 2013-12-06 | 2021-11-05 | 癌を治療するための併用療法 |
| JP2023122130A Pending JP2023139230A (ja) | 2013-12-06 | 2023-07-27 | 癌を治療するための併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20160303135A1 (OSRAM) |
| EP (2) | EP3888659A1 (OSRAM) |
| JP (4) | JP2016539134A (OSRAM) |
| KR (3) | KR20210117347A (OSRAM) |
| CN (2) | CN116019921A (OSRAM) |
| AU (2) | AU2014360078A1 (OSRAM) |
| BR (1) | BR112016012713A2 (OSRAM) |
| CA (1) | CA2931263A1 (OSRAM) |
| EA (1) | EA201691079A1 (OSRAM) |
| ES (1) | ES2863996T3 (OSRAM) |
| IL (3) | IL282741B2 (OSRAM) |
| MX (1) | MX373187B (OSRAM) |
| WO (1) | WO2015085325A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| US9175331B2 (en) * | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| IL308807B2 (en) | 2012-04-13 | 2025-08-01 | Epizyme Inc | Combination therapy for treating cancer |
| CN110898067A (zh) | 2012-10-15 | 2020-03-24 | Epizyme股份有限公司 | 癌症治疗方法 |
| US20150313906A1 (en) * | 2012-12-19 | 2015-11-05 | Glaxosmithkline Llc | Combination |
| PL3157527T3 (pl) | 2014-06-17 | 2023-08-07 | Epizyme, Inc. | Inhibitory ezh2 do leczenia chłoniaka |
| CN106794177A (zh) | 2014-10-16 | 2017-05-31 | Epizyme股份有限公司 | 治疗癌症的方法 |
| BR112017010166A2 (en) | 2014-11-17 | 2018-02-14 | Epizyme, Inc. | solid tumor treatment method, activity inhibition method, oral dosage form for treating a solid tumor, solid pharmaceutical formulation, process for preparing a pharmaceutical formulation, and solid pharmaceutical composition |
| CN108135908A (zh) | 2015-04-20 | 2018-06-08 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| JP6890097B2 (ja) | 2015-06-10 | 2021-06-18 | エピザイム，インコーポレイティド | リンパ腫を処置するためのｅｚｈ２阻害剤 |
| WO2017019721A2 (en) * | 2015-07-28 | 2017-02-02 | Constellation Pharmaceuticals, Inc. | Combination therapies for modulation of histone methyl modifying enzymes |
| CA2996412A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| SG10201909413SA (en) * | 2015-10-06 | 2019-11-28 | Epizyme Inc | Method of treating medulloblastoma with an ezh2 inhibitor |
| EP3386513A2 (en) * | 2015-12-07 | 2018-10-17 | Epizyme Inc | Inhibitors of ezh2 and methods of use thereof |
| CA3011186A1 (en) | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
| EA201892075A1 (ru) * | 2016-03-15 | 2019-04-30 | Оризон Дженомикс, С.А. | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей |
| JP7121660B2 (ja) | 2016-06-01 | 2022-08-18 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤の使用 |
| WO2017218953A1 (en) * | 2016-06-17 | 2017-12-21 | Epizyme, Inc. | Ezh2 inhibitors for treating cancer |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| CA3058241A1 (en) * | 2017-05-18 | 2018-11-22 | Jiangsu Hengrui Medicine Co., Ltd. | Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor |
| US11602529B2 (en) | 2017-06-02 | 2023-03-14 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| EP3654956A4 (en) | 2017-07-19 | 2021-04-28 | Children's Medical Center Corporation | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH IMPRESSION DEFECTS |
| WO2019050924A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | POLY THERAPY FOR THE TREATMENT OF CANCER |
| CN109718377B (zh) * | 2017-10-31 | 2021-03-26 | 中国科学院脑科学与智能技术卓越创新中心 | KPNB1抑制剂和Bcl-xL抑制剂在制备抗肿瘤药物中的应用 |
| US12396996B2 (en) | 2019-08-06 | 2025-08-26 | The General Hospital Corporation | Compounds, pharmaceutical compositions, and methods of their use in reversing cancer chemoresistance |
| CN112870366B (zh) * | 2019-11-29 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂在制备治疗肿瘤药物中的新用途 |
| US12138320B2 (en) * | 2020-05-11 | 2024-11-12 | The University Of Chicago | Composition and methods for tumor imaging and treatment |
| WO2024106879A1 (ko) * | 2022-11-17 | 2024-05-23 | 인제대학교 산학협력단 | Ezh2 저해제 및 btk 억제제를 포함하는, 암의 예방 또는 치료용 약제학적 조성물 |
| EP4471958A4 (en) | 2022-12-01 | 2025-05-07 | LG Energy Solution, Ltd. | BATTERY PACK |
| CN119662835B (zh) * | 2025-02-20 | 2025-05-27 | 宁波熙宁检测技术有限公司 | 一种用于检测ezh2基因突变的核酸组合物、试剂盒及检测方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| AU2011298987B2 (en) | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| EP2681216B1 (en) | 2011-02-28 | 2017-09-27 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| EP2760452A4 (en) | 2011-09-30 | 2015-04-01 | Glaxosmithkline Llc | METHODS OF TREATING CANCER |
| TR201904660T4 (tr) | 2012-03-12 | 2019-05-21 | Epizyme Inc | İnsan EZH2 inhibitörleri ve bunun kullanım yöntemleri. |
| DK3184523T3 (da) | 2012-04-13 | 2019-08-19 | Epizyme Inc | N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4' -(morphofinomethyl)-[1,1'-biphenyl]-3-carboxamidhydrobromid til anvendelse i behandlingen af en sygdom med celleproliferation i det hæmatologiske system. |
| IL308807B2 (en) * | 2012-04-13 | 2025-08-01 | Epizyme Inc | Combination therapy for treating cancer |
| WO2013173441A2 (en) * | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| CN110898067A (zh) | 2012-10-15 | 2020-03-24 | Epizyme股份有限公司 | 癌症治疗方法 |
| PE20150886A1 (es) | 2012-10-15 | 2015-06-04 | Epizyme Inc | Compuestos de benceno sustituidos |
| KR102229478B1 (ko) | 2012-11-01 | 2021-03-18 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료 |
| US20140120083A1 (en) * | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| AU2013361079B2 (en) | 2012-12-21 | 2018-07-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| US20150344427A1 (en) | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | 1,4-pyridone compounds |
| EP2970306A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS |
| EP2970281A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED BENZOL COMPOUNDS |
| RU2019134551A (ru) | 2013-05-30 | 2019-11-22 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| US9624205B2 (en) | 2013-07-19 | 2017-04-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2015010049A1 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted benzene compounds |
| SG11201602269QA (en) | 2013-10-16 | 2016-04-28 | Epizyme Inc | Hydrochloride salt form for ezh2 inhibition |
| US20160228447A1 (en) | 2013-10-18 | 2016-08-11 | Epizyme, Inc. | Method of treating cancer |
| PL3157527T3 (pl) | 2014-06-17 | 2023-08-07 | Epizyme, Inc. | Inhibitory ezh2 do leczenia chłoniaka |
| BR112017010166A2 (en) | 2014-11-17 | 2018-02-14 | Epizyme, Inc. | solid tumor treatment method, activity inhibition method, oral dosage form for treating a solid tumor, solid pharmaceutical formulation, process for preparing a pharmaceutical formulation, and solid pharmaceutical composition |
| CN108135908A (zh) | 2015-04-20 | 2018-06-08 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| JP6890097B2 (ja) | 2015-06-10 | 2021-06-18 | エピザイム，インコーポレイティド | リンパ腫を処置するためのｅｚｈ２阻害剤 |
-
2014
- 2014-12-08 CN CN202310008463.1A patent/CN116019921A/zh active Pending
- 2014-12-08 KR KR1020217029294A patent/KR20210117347A/ko not_active Withdrawn
- 2014-12-08 CN CN201480071510.6A patent/CN105873592B/zh active Active
- 2014-12-08 WO PCT/US2014/069167 patent/WO2015085325A1/en not_active Ceased
- 2014-12-08 BR BR112016012713A patent/BR112016012713A2/pt not_active Application Discontinuation
- 2014-12-08 EP EP21159972.5A patent/EP3888659A1/en not_active Withdrawn
- 2014-12-08 CA CA2931263A patent/CA2931263A1/en active Pending
- 2014-12-08 JP JP2016535691A patent/JP2016539134A/ja active Pending
- 2014-12-08 US US15/101,577 patent/US20160303135A1/en not_active Abandoned
- 2014-12-08 EP EP14868382.4A patent/EP3076977B1/en active Active
- 2014-12-08 ES ES14868382T patent/ES2863996T3/es active Active
- 2014-12-08 EA EA201691079A patent/EA201691079A1/ru unknown
- 2014-12-08 KR KR1020167017622A patent/KR102473113B1/ko active Active
- 2014-12-08 MX MX2016007351A patent/MX373187B/es active IP Right Grant
- 2014-12-08 KR KR1020227041774A patent/KR20220165809A/ko not_active Ceased
- 2014-12-08 IL IL282741A patent/IL282741B2/en unknown
- 2014-12-08 AU AU2014360078A patent/AU2014360078A1/en not_active Abandoned
-
2016
- 2016-05-19 IL IL245731A patent/IL245731B/en active IP Right Grant
-
2017
- 2017-11-10 US US15/809,445 patent/US10463671B2/en active Active
-
2019
- 2019-09-17 US US16/573,371 patent/US20200113911A1/en not_active Abandoned
- 2019-11-18 JP JP2019207594A patent/JP2020045350A/ja active Pending
-
2020
- 2020-03-24 AU AU2020202088A patent/AU2020202088B2/en not_active Ceased
-
2021
- 2021-11-05 JP JP2021180722A patent/JP7323592B2/ja active Active
- 2021-11-23 US US17/533,674 patent/US20220226336A1/en not_active Abandoned
-
2023
- 2023-07-27 JP JP2023122130A patent/JP2023139230A/ja active Pending
- 2023-07-30 IL IL304851A patent/IL304851A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539134A5 (OSRAM) | ||
| JP2017518334A5 (OSRAM) | ||
| TWI887465B (zh) | 用於伊卡洛斯(ikaros)或愛露斯(aiolos)介導之病症之有利療法 | |
| CY1122566T1 (el) | Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου | |
| CR20210045A (es) | Inhibidores de inflamasoma nlrp3 | |
| JP2017518302A5 (OSRAM) | ||
| JP2018524298A5 (OSRAM) | ||
| JP2017530984A5 (OSRAM) | ||
| CN111372588A (zh) | 与hsp90抑制剂相关的治疗方法 | |
| JP2018522045A5 (OSRAM) | ||
| JP2016525097A5 (OSRAM) | ||
| JP2019505529A5 (OSRAM) | ||
| JP2012513416A5 (OSRAM) | ||
| JP2016534071A5 (OSRAM) | ||
| ECSP12011703A (es) | Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos | |
| JP2015532296A5 (OSRAM) | ||
| JP2016539156A5 (OSRAM) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2017511377A5 (OSRAM) | ||
| RU2017119066A (ru) | Композии апилимода и способы их применения в лечении колоректального рака | |
| BR112017017211A2 (pt) | composto, composição, sal farmaceuticamente aceitável de um composto, combinação, formulação farmacêutica, métodos para matar uma micobactéria e/ou inibir a replicação de micobactérias que causam doença em um animal, para tratamento de uma infecção micobacteriana em um animal e para tratamento de uma doença resultante de uma infecção por micobactéria de um mamífero, e, uso de um composto. | |
| JP2016513124A5 (OSRAM) | ||
| CN113908159A (zh) | 西奥罗尼及其联合用药治疗非霍奇金淋巴瘤的用途 | |
| WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
| EP3787631B1 (en) | Modulators of orphan nuclear receptors for nash and other metabolic disorders |